Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A new, large-scale systematic review published in PLOS Neglected Tropical Diseases has identified clear, significant research gaps in the diagnosis and treatment of Chagas disease. The paper also highlights significant differences in study design, diagnostic methods, duration of follow-up, and the timing of outcome assessment used by investigators even in the last decade.

Two people discussing and pointing at information on a leaflet © Ana Ferreira, DNDi

This systematic review assessed the feasibility of establishing an individual participant-level data platform (IPD), and included clinical data from 23,116 patients from prospective Chagas disease studies published after 1997 with patients receiving a trypanocidal treatment. Researchers found that harnessing IPD from past studies could help to answer some outstanding research questions, and inform prospective data collection. Currently there are very limited options for the treatment of Chagas disease. The two major drugs, Benznidazole and nifurtimox, were both discovered half a century ago and have some limitations.

Existing IPD, collected in past clinical trials and longitudinal observational studies, could be pooled and used to generate new evidence to address knowledge gaps and guide research priorities to strengthen evidence for the treatment and diagnosis of Chagas disease.

The Chagas disease platform, launched by IDDO and the Drugs for Neglected Diseases Initiative (DNDi) in 2019 helps to strengthen collaboration between researchers and avoid duplication, both critical to the IPD analyses efforts.,

The full story is available on the IDDO website

Read the publication 'The Chagas disease study landscape: A systematic review of clinical and observational antiparasitic treatment studies to assess the potential for establishing an individual participant-level data platform' on the PLOS Neglected Tropical Diseases website

Similar stories

A new WWARN study supports safety of WHO recommended malaria treatment to advance elimination and reduce spread of artemisinin resistance

A new WWARN study, published in BMC Medicine, supports a World Health Organization (WHO) recommendation that a single primaquine target dose of 0.25 mg/kg is generally safe and well tolerated when given together with an ACT to treat malaria.

Routine surveillance data can provide an early warning system for antimalarial resistance in pre-elimination areas in Africa

In the first published study of its kind, a new WWARN paper in the Malaria Journal has created near-real-time maps to support antimalarial drug resistance monitoring, using routine malaria surveillance data and individually patient linked data on molecular markers of antimalarial drug resistance.

Oxford University launch new clinical trial to test a treatment for monkeypox

The team behind the world-leading RECOVERY trial of COVID-19 treatments are leading a new study investigating a potential treatment for people who have been diagnosed with monkeypox. The National Institute for Health and Care Research (NIHR) has commissioned and funded the study. The first patients have now been recruited.

Using mathematical modelling to fight malaria

Researchers have created a mathematical model to predict genetic resistance to antimalarial drugs in Africa to manage one of the biggest threats to global malarial control.

FORESFA and VIE project meetings

The Medicine Quality Research Group organised a multidisciplinary hybrid meeting at Keble College, Oxford, July 3 to 6, for the FORESFA project ‘Forensic epidemiology and impact of substandard and falsified antimicrobials on public health’, funded by a Wellcome Collaborative Award.

Incomplete reporting of COVID-19 disease severity criteria compromises meta-analysis

Patients affected by COVID-19 should be treated according to the severity of their disease. However, not all key national or international organisations define severity in the same way. This imprecision in severity assessment compromises the validity of some therapeutic recommendations. Using individual patient data would better guide and improve therapeutic recommendations for COVID-19.